Opthea Ltd Files March 2024 Corporate Presentation
Ticker: OPTEY · Form: 6-K · Filed: Mar 4, 2024 · CIK: 1815620
Sentiment: neutral
Topics: corporate-presentation, biopharmaceutical, sec-filing
TL;DR
Opthea dropped its March 2024 corporate presentation, giving investors a fresh look at their eye disease drug pipeline.
AI Summary
Opthea Limited filed a Form 6-K on March 4, 2024, to report its corporate presentation for March 2024. The filing includes a press release detailing the presentation, which likely covers the company's business, financial performance, and strategic outlook. Opthea is a biopharmaceutical company focused on developing novel therapies for serious eye conditions.
Why It Matters
This filing provides investors with an updated overview of Opthea's business strategy and progress, which could influence investment decisions regarding their pipeline and future prospects.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Opthea faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Players & Entities
- Opthea Limited (company) — Registrant
- March 2024 (date) — Presentation period
- 001-39621 (other) — SEC File Number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report Opthea Limited's corporate presentation for March 2024, which includes a press release.
What type of company is Opthea Limited?
Opthea Limited is a biopharmaceutical company specializing in the development of novel therapies for serious eye conditions.
When was this Form 6-K filed?
This Form 6-K was filed on March 4, 2024.
What exhibit is included with this filing?
Exhibit 99.1, a Press Release titled 'Opthea Corporate Presentation - March 2024', is included with this filing.
Does Opthea file annual reports under Form 20-F or 40-F?
Opthea files annual reports under Form 20-F, as indicated by the checkmark in the filing.
Filing Stats: 148 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-03-04 06:06:25
Filing Documents
- opt_corporate_presentati.htm (6-K) — 22KB
- opt-ex99_1.htm (EX-99.1) — 34KB
- opt-ex99_1s1.jpg (GRAPHIC) — 305KB
- opt-ex99_1s2.jpg (GRAPHIC) — 1113KB
- opt-ex99_1s3.jpg (GRAPHIC) — 282KB
- opt-ex99_1s4.jpg (GRAPHIC) — 462KB
- opt-ex99_1s5.jpg (GRAPHIC) — 425KB
- opt-ex99_1s6.jpg (GRAPHIC) — 344KB
- opt-ex99_1s7.jpg (GRAPHIC) — 364KB
- opt-ex99_1s8.jpg (GRAPHIC) — 415KB
- opt-ex99_1s9.jpg (GRAPHIC) — 322KB
- opt-ex99_1s10.jpg (GRAPHIC) — 309KB
- opt-ex99_1s11.jpg (GRAPHIC) — 384KB
- opt-ex99_1s12.jpg (GRAPHIC) — 211KB
- opt-ex99_1s13.jpg (GRAPHIC) — 417KB
- opt-ex99_1s14.jpg (GRAPHIC) — 381KB
- opt-ex99_1s15.jpg (GRAPHIC) — 448KB
- opt-ex99_1s16.jpg (GRAPHIC) — 311KB
- opt-ex99_1s17.jpg (GRAPHIC) — 361KB
- opt-ex99_1s18.jpg (GRAPHIC) — 301KB
- opt-ex99_1s19.jpg (GRAPHIC) — 426KB
- opt-ex99_1s20.jpg (GRAPHIC) — 316KB
- opt-ex99_1s21.jpg (GRAPHIC) — 278KB
- opt-ex99_1s22.jpg (GRAPHIC) — 380KB
- opt-ex99_1s23.jpg (GRAPHIC) — 412KB
- opt-ex99_1s24.jpg (GRAPHIC) — 470KB
- opt-ex99_1s25.jpg (GRAPHIC) — 319KB
- opt-ex99_1s26.jpg (GRAPHIC) — 220KB
- opt-ex99_1s27.jpg (GRAPHIC) — 361KB
- opt-ex99_1s28.jpg (GRAPHIC) — 348KB
- opt-ex99_1s29.jpg (GRAPHIC) — 462KB
- opt-ex99_1s30.jpg (GRAPHIC) — 245KB
- 0000950170-24-024332.txt ( ) — 15743KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 3/04/2024